Yat Sun Or
CIK: 0001571212
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ENANTA PHARMACEUTICALS INC
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Feb 12, 2026ENTA
ENANTA PHARMACEUTICALS INC
Award(A)Direct1.7K shares- - Feb 12, 2026ENTA
ENANTA PHARMACEUTICALS INC
Tax Payment(F)Direct3.4K shares at avg. $14.25$49K - Feb 12, 2026ENTA
ENANTA PHARMACEUTICALS INC
Award(A)Direct5.2K shares- - Dec 5, 2025ENTA
ENANTA PHARMACEUTICALS INC
Sale(S)Direct2.4K shares at avg. $14.23$34K - Dec 1, 2025ENTA
ENANTA PHARMACEUTICALS INC
Tax Payment(F)Direct753 shares at avg. $14.12$11K - Nov 25, 2025ENTA
ENANTA PHARMACEUTICALS INC
Award(A)DirectStock Option (right to buy)
110K shares- - Feb 12, 2025ENTA
ENANTA PHARMACEUTICALS INC
Tax Payment(F)Direct4.3K shares at avg. $5.59$24K - Feb 12, 2025ENTA
ENANTA PHARMACEUTICALS INC
Award(A)Direct9.8K shares- - Dec 6, 2024ENTA
ENANTA PHARMACEUTICALS INC
Sale(S)Direct2.6K shares at avg. $8.06$21K - Dec 1, 2024ENTA
ENANTA PHARMACEUTICALS INC
Tax Payment(F)Direct1.6K shares at avg. $8.60$14K - Nov 27, 2024ENTA
ENANTA PHARMACEUTICALS INC
Award(A)DirectStock Option (right to buy)
87K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 12, 2026 | ENTA ENANTA PHARMACEUTICALS INC | Award(A) | 1,650 | - | $0 | Direct |
| Feb 12, 2026 | ENTA ENANTA PHARMACEUTICALS INC | Tax Payment(F) | 3,413 | $14.25 | $48,635 | Direct |
| Feb 12, 2026 | ENTA ENANTA PHARMACEUTICALS INC | Award(A) | 5,225 | - | $0 | Direct |
| Dec 5, 2025 | ENTA ENANTA PHARMACEUTICALS INC | Sale(S) | 2,390 | $14.23 | $34,010 | Direct |
| Dec 1, 2025 | ENTA ENANTA PHARMACEUTICALS INC | Tax Payment(F) | 753 | $14.12 | $10,632 | Direct |
| Nov 25, 2025 | ENTA ENANTA PHARMACEUTICALS INC | Award(A) Stock Option (right to buy) | 110,000 | - | - | Direct |
| Feb 12, 2025 | ENTA ENANTA PHARMACEUTICALS INC | Tax Payment(F) | 4,324 | $5.59 | $24,171 | Direct |
| Feb 12, 2025 | ENTA ENANTA PHARMACEUTICALS INC | Award(A) | 9,750 | - | - | Direct |
| Dec 6, 2024 | ENTA ENANTA PHARMACEUTICALS INC | Sale(S) | 2,591 | $8.06 | $20,883 | Direct |
| Dec 1, 2024 | ENTA ENANTA PHARMACEUTICALS INC | Tax Payment(F) | 1,595 | $8.60 | $13,717 | Direct |
| Nov 27, 2024 | ENTA ENANTA PHARMACEUTICALS INC | Award(A) Stock Option (right to buy) | 87,000 | - | - | Direct |
1-11 of 11 transactions
About Or Yat Sun
Or Yat Sun (SEC CIK 0001571212) files insider reports with the SEC as Chief Scientific Officer of ENANTA PHARMACEUTICALS INC (ENTA).
Signal8 holds 8 ownership filings by Or Yat Sun, all Form 4s, filed between Nov 27, 2024 and Feb 13, 2026. Those filings report 11 transactions, from Nov 27, 2024 to Feb 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Or Yat Sun's filings is in WATERTOWN, MA.
Recent filings by Or Yat Sun
- Feb 12, 2026: Grant or award of ENTA shares (Form 4, code A).
- Feb 12, 2026: Tax withholding of ENTA shares (Form 4, code F).
- Feb 12, 2026: Grant or award of ENTA shares (Form 4, code A).
- Dec 5, 2025: Open-market sale of ENTA shares (Form 4, code S).
- Dec 1, 2025: Tax withholding of ENTA shares (Form 4, code F).
Other insiders filing for ENANTA PHARMACEUTICALS INC (ENTA)
- Rottinghaus Scott T., Chief Medical Officer
- Vance Terry, Director
- Russell Lesley, Director
- Peterson Kristine, Director
- Hata Yujiro S, Director
- FOLETTA MARK G, Director